Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
复制标题
DOI：
10.1038/bjc.1994.331
复制
发表时间：
1994-09
影响因子：
8.8
通讯作者：
Homma, T.
中科院分区：
文献类型：
--
作者：
Kawa, S.;Tokoo, M.;Hasebe, O.;Hayashi, K.;Imai, H.;Oguchi, H.;Kiyosawa, K.;Furuta, S.;Homma, T.
对一种新的肿瘤标志物CA242和CA19-9进行了比较研究，特别参考了它们在胰腺癌中的诊断价值。CA242对胰腺癌的全部病例和早期病例（I期肿瘤）的敏感性与CA19-9相似。除结直肠癌外，其他恶性肿瘤CA242的阳性率均低于CA19-9。CA242的一个重要特点是，在慢性胰腺炎、慢性肝炎、肝硬化等良性疾病患者的血清中，CA242仅轻微且罕见升高。这一特征在良性梗阻性黄疸患者中更为明显，表明该标志物的血清水平几乎不受胆汁淤积的影响。采用90%特异性的截断水平，CA242在胰腺癌诊断中的临床结果与CA19-9相似，只是在一些早期胰腺癌患者中CA19-9呈假阴性。这些发现表明该标志物在首次就诊的患者中筛查胰腺癌的有用性。然而，CA242被发现受Lewis血型系统的影响。这一不利结果归因于该检测系统的C241捕集器抗体，该抗体与C50和NS19-9单克隆抗体具有几乎相同的表位特异性。综上所述，CA242具有更高的特异性，在诊断胰腺癌方面优于CA19-9。
A comparative study of a new tumour marker, CA242, and CA19-9 was conducted with special reference to their diagnostic usefulness in pancreatic cancer. CA242 showed sensitivity similar to that of CA19-9 for overall cases and early cases (stage I tumour) of pancreatic cancer. For other malignancies, the positive rates of CA242 were lower than those of CA19-9 except for colorectal cancer. An important characteristics of CA242 was that it was only slightly and infrequently elevated in the sera of patients with benign diseases such as chronic pancreatitis, chronic hepatitis and liver cirrhosis. This characteristic was more apparent in the patients with benign obstructive jaundice, indicating that the serum level of this marker was scarcely affected by cholestasis. Using cut-off levels corresponding to a 90% specificity, the clinical results obtained with CA242 in the diagnosis of pancreatic cancer were similar to those obtained with CA19-9, except that CA19-9 was falsely negative in some patients with early-stage pancreatic cancer. These findings suggest the usefulness of this marker for screening pancreatic cancer in patients on their first hospital visit. However, CA242 was found to be influenced by the Lewis blood group system. This unfavourable result is attributed to the C241 catcher antibody of this assay system, which has almost the same epitope specificity as the C50 and the NS19-9 monoclonal antibodies. In conclusion, CA242 is superior to CA19-9 in diagnosing pancreatic cancer by virtue of its higher specificity.
登录
查看更多内容
影响因子：
8.8
作者：
Kuusela P;Haglund C;Roberts PJ
通讯作者：
Roberts PJ
影响因子：
24.5
作者：
SCHMIEGEL, WH;KREIKER, C;THIELE, HG
通讯作者：
THIELE, HG
影响因子：
8.8
作者：
Haglund, C;Lindgren, J;Roberts, P J;Kuusela, P;Nordling, S
通讯作者：
Nordling, S
Ca242在胃肠癌中的敏感性和特异性。与CEA，CA50和CA 19-9的比较。
影响因子：
8.8
作者：
Nilsson, O;Johansson, C;Glimelius, B;Persson, B;Norgaard-Pedersen, B;Andren-Sandberg, A;Lindholm, L
通讯作者：
Lindholm, L
影响因子：
1.9
作者：
KOBAYASHI, T;KAWA, S;HOMMA, T
通讯作者：
HOMMA, T